Alkyl Amines Chemicals Ltd
ALKYLAMINEAlkyl Amines Chemicals Ltd's stock has fallen further than its earnings. EPS fell 3.3% in a year while the price moved −8.0%.
Biggest watch item: the price is already 12 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (12 weeks in) while the P/E sits at the 48th percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +93.9% year on year, and 151% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Alkyl Amines Chemicals Ltd trades at ₹1,868, in a confirmed uptrend and 12 weeks into that stage. That is +5.0% against its own 200-day average. It sits at 76% of a 52-week range of ₹1,278 to ₹2,053. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 6 straight weeks.
Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹1,868 it trades +5.0% versus its 200-day average and sits at 76% of its 52-week range (₹1,278–₹2,053).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +1,349% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Alkyl Amines Chemicals Ltd's story is not scored yet against the markers our research file set on 6 September 2026. Marker count: 12 not due yet. Still open: [object Object] · [object Object] · [object Object] · [object Object]
Our read, 6 September 2026. Alkyl Amines' June-2026 profit surge is mostly a war-driven inventory release and raw-material-to-selling-price timing spread that management itself says will settle back, sitting on a business whose returns have halved since 2022 and whose recovery is one quarter old — the debt-free balance sheet and the ended capex cycle are real and durable, but the operating improvement is not yet proven.
What is not proven yet. [object Object] · [object Object] · [object Object] · [object Object]
The test written in advance. Quarterly operating margin and the inventory-change line, Sep-2026 quarter — OPM falls back to the 18-19% pre-war range while inventory is rebuilt at Rs 100+/kg ammonia — proving the June spike was a one-off — Quarterly operating margin and the inventory-change line, Sep-2026 quarter.
The test written in advance. Kurkumbh plant commissioning and first new-product revenue — A fourth slip, or another quarter with no disclosure — extending a 6-7 month record of misses — Kurkumbh plant commissioning and first new-product revenue by FY27-Q2 (Nov-2026 call).
The test written in advance. FY27 volume growth against the redefined 5-10% 'normal' — Another mid-year cut to the baseline — a third consecutive downgrade — FY27 volume growth against the redefined 5-10% 'normal' FY26 volumes about flat; 'normal' redefined from 10-15% to 5-10% on the May-2026 call by FY27-Q2 and FY27-Q4 calls.
Lever 1 · Operating leverage — BUILDING. FCF Rs 154/67/102 crore across Mar 2024/25/26 (Rs 323 crore total); investing outflow -277 (Mar 2023) to -137 (Mar 2026); OCF Rs 777 crore vs PAT Rs 515 crore over FY24-26 (150.87%); FY27 capex guided Rs 80-90 crore; borrowings Rs 88 crore to Rs 1 crore. What proves it keeps working: Kanchan Shinde: 'it will be around INR80 crores to INR90 crores' for FY27; Kirat Patel: 'the capex looking at is just completing this project and maintenance capex'. It stops working if OCF fell with the profit trough (275 to 263 to 239) and inventory days fell 85 to 57, a release that reverses on restocking at Rs 100+/kg ammonia — so the cash level is not yet growing, only the capex cycle has turned.
Lever 4 · Paying down debt — ACTIVE. Borrowings Rs 88 crore (Mar 2023) to Rs 1 crore (Mar 2026); derived debt/equity 0.0007; interest cover 213; interest expense Rs 1 crore in FY26. It stops working if An unanswered Rs 136.7 crore spike in other financial liabilities (vs Rs 1.5 crore a year earlier) was raised on the May-2026 call as the line dropped — an open item the packet cannot check.
Lever 5 · Regulatory approval — BUILDING. Acetonitrile price from Rs 140-150/kg (FY26 average) to a bit over Rs 200/kg; Chinese imports reduced after they raised their own prices; company share increasing (management statement); benefit began Q4 FY26, two quarters later than first guided. What proves it keeps working: 'In the last quarter... they have reduced their imports because they have raised their prices. So more and more, our market share has been increasing.'
Lever 7 · Consolidation — BUILDING. Ethylamines: two players globally (Alkyl and Balaji), market 30,000-35,000 tons, prices stabilized and up to about Rs 200/kg on higher alcohol cost, stable share; methylamines: four players, 80,000-90,000 tons demand vs more than 150,000 tons capacity. What proves it keeps working: 'Ethyl has been only 2 of us, Balaji and us in the market... prices have stabilized. In fact, they have also increased because alcohol has increased and margins have been protected there.'
Sources: Y-skill two-pass review (glm-5.3:cloud), rubric Y-OL-1, question set YQ-2, 2026-09-06; Instruction bundle sha d59418593786aba12de34a87b5c26bfbc882f5bf32d1fdaa501a2c38c970c592. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Alkyl Amines Chemicals Ltd reported ₹528 Cr of revenue in the Jun 26 quarter, +30.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at 12.2% a year. The last full year, FY26, came in at ₹1,536 Cr. The last four reported quarters add to ₹1,658 Cr.
FY26 revenue came in at ₹1,536 Cr (−2.3% on the year), capping 10 years at 12.2% compound. The latest quarter (Jun 26) printed ₹528 Cr, +30.0% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +4.9% growth against the decade's 12.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +5.1% over the last 4 quarters against +7.6%/yr over the last 8 — stabilising; TTM profit +21.0% vs +23.7%/yr — stabilising.
FY26-Q4. Revenue 387 cr, PAT 45 cr, OPM 18.3% — this review produced no quarter-level why; see the levers.
FY27-Q1. Revenue 528 cr, PAT 95 cr, OPM 25.4% — this review produced no quarter-level why; see the levers.
Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Alkyl Amines Chemicals Ltd's operating margin is 25.0% in the Jun 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 18 fiscal years the operating margin has ranged 11.0% to 35.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 25.0%, +6.0 pp against the same quarter a year ago. Across 18 fiscal years the operating margin has ranged 11.0%–35.0%.
Why the margin moved: operating margin went +6.4 pp year on year while gross margin went +3.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
FY26-Q4. Revenue 387 cr, PAT 45 cr, OPM 18.3% — this review produced no quarter-level why; see the levers.
FY27-Q1. Revenue 528 cr, PAT 95 cr, OPM 25.4% — this review produced no quarter-level why; see the levers.
Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Alkyl Amines Chemicals Ltd earned ₹95.0 Cr of net profit in the Jun 26 quarter, +93.9% year on year. Full-year FY26 profit was ₹180 Cr. The 10-year compound rate is 13.7%. That is 18.0% of the quarter's revenue. The same quarter a year earlier earned ₹49.0 Cr.
Jun 26 profit was ₹95.0 Cr, +93.9% year on year. On the full year, FY26 printed ₹180 Cr (−3.2%), and the 10-year compound rate is 13.7%.
Why profit moved: revenue contributed +30.0% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +19.7% vs revenue +4.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
FY26-Q4. Revenue 387 cr, PAT 45 cr, OPM 18.3% — this review produced no quarter-level why; see the levers.
FY27-Q1. Revenue 528 cr, PAT 95 cr, OPM 25.4% — this review produced no quarter-level why; see the levers.
Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 151% of Alkyl Amines Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹239 Cr of operating cash against ₹180 Cr of profit. After ₹121 Cr of capital spending, ₹118 Cr was left as free cash.
FY26: operating cash of ₹239 Cr against reported profit of ₹180 Cr, leaving free cash of ₹118 Cr after ₹121 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 151% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 151%: the cash cycle stretched 17 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Alkyl Amines Chemicals Ltd's cash conversion cycle runs 42 days in FY26, up from 25 days in FY21. Capital spending ran ₹276 Cr over the last 3 years. At FY26 sales of ₹1,536 Cr each day of that cycle holds about ₹4.2 Cr, so roughly ₹177 Cr sits inside the business at any moment.
FY26: debtors at 55 days, inventory at 57 days — roughly 1.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 42 days, looser than FY21's 25.
The full loop: cash goes out to suppliers and production on day 0; stock waits 57 days to sell; customers pay about 55 days after that; and suppliers themselves are paid at 70 days — netting out to the 42-day cycle.
In money terms: at FY26 sales of ₹1,536 Cr, each day of the cycle holds about ₹4.2 Cr — so the 42-day loop keeps roughly ₹177 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹276 Cr over the last 3 fiscal years against ₹202 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹130 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Alkyl Amines Chemicals Ltd earns a ROCE of 17% in FY26. That is up from a trough of 11% in FY09. Return on invested capital clears the cost of that capital by +3.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.7% net margin on 0.81× asset turns.
FY26 ROCE is 17%, recovered from a FY09 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 11.7% net margin × 0.81× asset turns × 1.24× balance-sheet leverage ≈ 11.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 15.9% − 12.0% = a +3.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Alkyl Amines Chemicals Ltd carries total debt of ₹1.0 Cr against shareholder equity of ₹1,533 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.06 in FY21 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹1.0 Cr against shareholder equity of ₹1,533 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.06 (FY21) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 2.0 points of Alkyl Amines Chemicals Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 3.1% of the company. Foreign institutions moved +0.4 points over the same window, to 3.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +2.0 points over 8 quarters to 3.1%; Foreign institutions: +0.4 points over 8 quarters to 3.5%; Promoters: +0.1 points over 8 quarters to 72.0%.
Why the register moved: domestic institutions drove it (+2.0 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Alkyl Amines Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Alkyl Amines Chemicals Ltd trades at 42.4× P/E, mid-range by its own standards (48th percentile). Its long-run median P/E is 43.7×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 42.4× is mid-range by its own standards (48th percentile), against a long-run median of 43.7× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −3.3% against a −8.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −14.7%/yr price move, ~−6.9%/yr came from earnings growth and ~−7.8 pp from the multiple (compressing); over 10y, of the +31.1%/yr price move, ~+16.5%/yr came from earnings growth and ~+14.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Alkyl Amines Chemicals Ltd was paying for profit growth of about 24.3% a year. Profit itself has compounded 13.7% a year over the past 10 years. Today the market pays 42.4× P/E, the 48th percentile of its own 11-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Alkyl Amines Chemicals Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −26.4% and has held its recovery at +21.0%, ROCE holding at 15.1%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −2.3% | −3.0% | +4.3% | +12.2% |
| Profit | −3.2% | −7.7% | −9.4% | +13.7% |
| EPS | −3.3% | −7.7% | −9.5% | +13.7% |
| Share price | −8.0% | −9.1% | −14.7% | +31.1% |
4-Factor Sector Score
46.8/100 — rank 17 of 28 in Speciality Chemicals · 100% evidence confidence
Alkyl Amines Chemicals Ltd scores 46.8 out of 100 against the 28 companies it is compared with in Speciality Chemicals, ranking 17. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 18.4 + 15.6 + 5.6 + 7.2 = 46.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Quarterly scorecard
12 markers came out of our Alkyl Amines Chemicals Ltd research file of 6 September 2026, and each results season scores every one of them. No results season has been scored against them yet. A row is permanent: a miss stays on the record after it is fixed.
| Marker | The bar | Where it stands | Score |
|---|---|---|---|
| M1 | Quarterly operating margin and the inventory-change line, Sep-2026 quarter — OPM falls back to the 18-19% pre-war range while inventory is rebuilt at Rs 100+/kg ammonia — proving the June spike was a one-off | Not checked yet. | PENDING |
| M10 | Ammonia price versus finished-goods price spread | Not checked yet. | PENDING |
| M11 | The Rs 136.7 crore other-financial-liabilities item | Not checked yet. | PENDING |
| M12 | Methylamines overcapacity absorption — price and volume behavior | Not checked yet. | PENDING |
| M2 | Kurkumbh plant commissioning and first new-product revenue — A fourth slip, or another quarter with no disclosure — extending a 6-7 month record of misses (Kurkumbh plant commissioning and first new-product revenue) | Not checked yet. | PENDING |
| M3 | FY27 volume growth against the redefined 5-10% 'normal' — Another mid-year cut to the baseline — a third consecutive downgrade (FY27 volume growth against the redefined 5-10% 'normal') | Not checked yet. | PENDING |
| M4 | Ammonia price versus finished-goods price spread — Finished goods fall as fast as or faster than ammonia, compressing spreads to or below pre-war (Ammonia price versus finished-goods price spread) | Not checked yet. | PENDING |
| M5 | The Rs 136.7 crore other-financial-liabilities item — An undisclosed borrowing-like obligation on a supposedly debt-free balance sheet (The Rs 136.7 crore other-financial-liabilities item) | Not checked yet. | PENDING |
| M6 | Methylamines overcapacity absorption — price and volume behavior — Price war or share loss in methylamines dragging the ethylamines/ACN gains | Not checked yet. | PENDING |
| M7 | Quarterly operating margin and the inventory-change line, Sep-2026 quarter | Not checked yet. | PENDING |
| M8 | Kurkumbh plant commissioning and first new-product revenue | Not checked yet. | PENDING |
| M9 | FY27 volume growth against the redefined 5-10% 'normal' | Not checked yet. | PENDING |
Said versus delivered
What Alkyl Amines Chemicals Ltd's management promised, set against what actually arrived — 3 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
🚨 New Product Commissioning Timeline - Successive Delays Without Substantive Justification · 6 May 2026. The May 2025 call guided mechanical completion of the new product plant by December 2025 or January 2026, while the Nov 2025 call slipped this to February-March 2026 with Q1 FY27 commercialization. The May 2026 call reveals mechanical completion is still pending and now expected only by end of June 2026, pushing commissioning to the start of Q2 FY27 - a cumulative slip of approximately 6-7 months from the original target - described only as a slight delay with no substantive explanation offered.
Ammonia Supply Risk Assessment - Direct Reversal From Prior Dismissal · 6 May 2026. In the Nov 2025 call, management explicitly downplayed the risk of Middle East ammonia supply disruptions, asserting the impact of Iranian sanctions on the supply chain would not be long-lasting and would settle very quickly. The May 2026 call directly contradicts this, disclosing that the company faced grave concerns over availability in March 2026, with prices roughly doubling, and supply chain normalization now expected to take another 3-6 months.
Volume Growth Normal Rate - Quietly Redefined Downward · 6 May 2026. Both prior calls explicitly described 10-15% annual volume growth as the company's normal expectation, with the Nov 2025 call treating it as the rate to return to once geopolitical headwinds subsided. The May 2026 call guides to 5-10% volume growth for FY27 and explicitly describes this as a normal year, effectively lowering the stated baseline growth rate by approximately half without explaining whether this represents a temporary adjustment or a structural reset in long-term growth expectations.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Panama Petrochem LtdPANAMAPET | 74.9/100Favorable setup100% evidence | LEADER | 28.1/35 Revenue 45.9% · PAT 100% · OPM change 14 pp 100% evidence | 14.9/25 ROCE 19.2% · OPM 22% 100% evidence | 15.4/20 P/E 6.1× · PEG 0.55 100% evidence | 16.5/20 RS sector 18.7% · RS bench 46.9% · 1Y 64.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.1 + 14.9 + 15.4 + 16.5 = 74.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sunshield Chemicals Ltd530845 | 69.8/100Favorable setup76% evidence | FADING | 28.0/35 Revenue 12.9% · PAT 100% · OPM change 5 pp 95% evidence | 16.6/25 ROCE 19.9% · OPM 16% 76% evidence | 11.3/20 P/E 29.1× · PEG — 50% evidence | 13.9/20 RS sector 2.3% · RS bench 24.5% · 1Y 16.2%10 of 11 weeks ahead 70% evidence |
| Exact sum: 28 + 16.6 + 11.3 + 13.9 = 69.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Vikram Thermo (India) Ltd530477 | 65.5/100Favorable setup67% evidence | BREAKING OUT | 25.5/35 Revenue 16.9% · PAT 41.9% · OPM change 8 pp 95% evidence | 19.8/25 ROCE 36.2% · OPM 48% 76% evidence | 7.9/20 P/E 24.3× · PEG — 50% evidence | 12.3/20 RS sector — · RS bench 83.6% · 1Y —10 of 10 weeks ahead 25% evidence |
| Exact sum: 25.5 + 19.8 + 7.9 + 12.3 = 65.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 4Black Rose Industries LtdBLACKROSE | 64.2/100Mixed-positive evidence72% evidence | BREAKING OUT | 22.0/35 Revenue 8.6% · PAT 28.6% · OPM change 6 pp 95% evidence | 17.1/25 ROCE 18.7% · OPM 16% 95% evidence | 14.5/20 P/E 19.2× · PEG — 50% evidence | 10.6/20 RS sector — · RS bench 11.6% · 1Y —4 of 6 weeks ahead 25% evidence |
| Exact sum: 22 + 17.1 + 14.5 + 10.6 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Yasho Industries LtdYASHO | 62.9/100Mixed-positive evidence87% evidence | BREAKING OUT | 29.3/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence | 8.6/25 ROCE 8.9% · OPM 24% 100% evidence | 12.0/20 P/E 87.6× · PEG 1.15 65% evidence | 13.0/20 RS sector -2.4% · RS bench 102% · 1Y 131.1%11 of 11 weeks ahead 70% evidence |
| Exact sum: 29.3 + 8.6 + 12 + 13 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Privi Speciality Chemicals LtdPRIVISCL | 59.9/100Mixed-positive evidence75% evidence | FADING | 25.0/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence | 17.9/25 ROCE 22.3% · OPM 23% 76% evidence | 9.5/20 P/E 39.7× · PEG — 15% evidence | 7.5/20 RS sector -8.1% · RS bench 15.3% · 1Y 55.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 17.9 + 9.5 + 7.5 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aether Industries LtdAETHER | 58.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 24.4/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence | 10.7/25 ROCE 11.9% · OPM 31% 100% evidence | 4.2/20 P/E 92.6× · PEG 8.9 100% evidence | 19.1/20 RS sector 23.6% · RS bench 53.6% · 1Y 125.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.7 + 4.2 + 19.1 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8DMCC Speciality Chemicals LtdDMCC | 56.8/100Mixed-positive evidence80% evidence | TURNING | 24.4/35 Revenue 49.7% · PAT 42.9% · OPM change 0 pp 95% evidence | 11.0/25 ROCE 14.8% · OPM 13% 95% evidence | 11.4/20 P/E 17.9× · PEG — 15% evidence | 10.0/20 RS sector -12.3% · RS bench 10% · 1Y -6.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 11 + 11.4 + 10 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Pidilite Industries LtdPIDILITIND | 56.7/100Mixed-positive evidence100% evidence | FADING | 22.6/35 Revenue 14.1% · PAT 21.5% · OPM change 1 pp 100% evidence | 20.6/25 ROCE 31% · OPM 26% 100% evidence | 7.9/20 P/E 60.2× · PEG 3.8 100% evidence | 5.6/20 RS sector -15.4% · RS bench 6.4% · 1Y 1.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 20.6 + 7.9 + 5.6 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Tatva Chintan Pharma Chem LtdTATVA | 56.0/100Mixed-positive evidence93% evidence | BREAKING OUT | 30.4/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence | 6.5/25 ROCE 7.2% · OPM 19% 100% evidence | 4.7/20 P/E 71.8× · PEG 5.63 65% evidence | 14.4/20 RS sector -1.5% · RS bench 23.3% · 1Y 61.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.4 + 6.5 + 4.7 + 14.4 = 56 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Fineotex Chemical LtdFCL | 54.0/100Mixed-positive evidence100% evidence | LEADER | 18.4/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence | 12.7/25 ROCE 18.3% · OPM 16% 100% evidence | 3.0/20 P/E 54.9× · PEG 4.19 100% evidence | 19.9/20 RS sector 58% · RS bench 94.1% · 1Y 143.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 12.7 + 3 + 19.9 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Aarti Industries LtdAARTIIND | 53.5/100Mixed-positive evidence100% evidence | BREAKING OUT | 27.7/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence | 8.3/25 ROCE 6.9% · OPM 16% 100% evidence | 9.0/20 P/E 34.2× · PEG 2.05 100% evidence | 8.5/20 RS sector -8.2% · RS bench 15.1% · 1Y 30.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 27.7 + 8.3 + 9 + 8.5 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Kronox Lab Sciences LtdKRONOX | 53.3/100Mixed-positive evidence65% evidence | BREAKING OUT | 9.4/35 Revenue 6.1% · PAT 11.6% · OPM change -1.1 pp 95% evidence | 21.6/25 ROCE 36% · OPM 31.7% 95% evidence | 10.8/20 P/E 22.8× · PEG — 15% evidence | 11.5/20 RS sector — · RS bench 24.8% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 9.4 + 21.6 + 10.8 + 11.5 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Chemcon Speciality Chemicals LtdCHEMCON | 51.1/100Mixed-positive evidence81% evidence | TURNING | 21.0/35 Revenue 16.7% · PAT 12% · OPM change 8 pp 95% evidence | 10.7/25 ROCE 6.3% · OPM 23% 95% evidence | 12.1/20 P/E 28.2× · PEG — 50% evidence | 7.3/20 RS sector -21.7% · RS bench 13.7% · 1Y 4.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 10.7 + 12.1 + 7.3 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Vishnu Chemicals LtdVISHNU | 47.7/100Mixed-negative evidence100% evidence | BREAKING OUT | 15.5/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence | 11.3/25 ROCE 16.4% · OPM 15% 100% evidence | 5.6/20 P/E 32.1× · PEG 2.82 100% evidence | 15.3/20 RS sector 4.7% · RS bench 31.2% · 1Y 48.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.3 + 5.6 + 15.3 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 31.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Galaxy Surfactants LtdGALAXYSURF | 47.3/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.5/35 Revenue 27% · PAT 15.7% · OPM change 4 pp 100% evidence | 9.4/25 ROCE 13.5% · OPM 14% 100% evidence | 9.6/20 P/E 21.3× · PEG 4.39 100% evidence | 8.8/20 RS sector -12.1% · RS bench 11.3% · 1Y -6.7%8 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 9.4 + 9.6 + 8.8 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Alkyl Amines Chemicals Ltdthis pageALKYLAMINE | 46.8/100Mixed-negative evidence100% evidence | FADING | 18.4/35 Revenue 5.1% · PAT 21% · OPM change 6 pp 100% evidence | 15.6/25 ROCE 16.6% · OPM 25% 100% evidence | 5.6/20 P/E 42.4× · PEG 5.37 100% evidence | 7.2/20 RS sector -10.8% · RS bench 11.6% · 1Y -9.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 15.6 + 5.6 + 7.2 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Vinati Organics LtdVINATIORGA | 44.4/100Mixed-negative evidence82% evidence | TURNING | 11.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence | 17.5/25 ROCE 19.8% · OPM 24% 76% evidence | 13.4/20 P/E 29.9× · PEG — 50% evidence | 2.3/20 RS sector -28.7% · RS bench -9.8% · 1Y -23.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 17.5 + 13.4 + 2.3 = 44.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Amal LtdAMAL | 43.0/100Mixed-negative evidence69% evidence | 8.0/35 Revenue 79% · PAT -23.1% · OPM change -7 pp 95% evidence | 16.4/25 ROCE 26% · OPM 18% 76% evidence | 10.0/20 P/E 30.7× · PEG — 15% evidence | 8.6/20 RS sector -18.2% · RS bench 15.4% · 1Y -20%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 8 + 16.4 + 10 + 8.6 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Platinum Industries LtdPLATIND | 42.5/100Mixed-negative evidence74% evidence | BASING | 12.8/35 Revenue 9.6% · PAT 6.5% · OPM change -1 pp 95% evidence | 12.3/25 ROCE 15.7% · OPM 12% 95% evidence | 10.6/20 P/E 23.9× · PEG — 15% evidence | 6.8/20 RS sector -10.6% · RS bench -6.1% · 1Y -22.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.3 + 10.6 + 6.8 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Grauer & Weil (India) LtdGRAUWEIL | 41.5/100Mixed-negative evidence100% evidence | TURNING | 10.4/35 Revenue 10.1% · PAT 6.6% · OPM change -5 pp 100% evidence | 16.1/25 ROCE 20.6% · OPM 16% 100% evidence | 8.2/20 P/E 21.4× · PEG 4.01 100% evidence | 6.8/20 RS sector -17.8% · RS bench 3.4% · 1Y -18.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 16.1 + 8.2 + 6.8 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Anupam Rasayan India LtdANURAS | 41.5/100Mixed-negative evidence82% evidence | ASLEEP | 20.0/35 Revenue 51.7% · PAT 14.8% · OPM change -1 pp 95% evidence | 10.5/25 ROCE 7.4% · OPM 25% 76% evidence | 8.3/20 P/E 79.5× · PEG — 50% evidence | 2.7/20 RS sector -21.7% · RS bench -1% · 1Y 9.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 10.5 + 8.3 + 2.7 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Neogen Chemicals LtdNEOGEN | 40.5/100Mixed-negative evidence90% evidence | LEADER | 14.7/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence | 6.7/25 ROCE 6.5% · OPM 19% 100% evidence | 5.2/20 P/E 183× · PEG — 50% evidence | 13.9/20 RS sector 22.9% · RS bench 52% · 1Y 59.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 6.7 + 5.2 + 13.9 = 40.5 · Decision use: Price leads the evidence: RS versus the benchmark is 52%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 24Paushak LtdPAUSHAKLTD | 37.0/100Mixed-negative evidence81% evidence | BREAKING OUT | 11.9/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence | 10.0/25 ROCE 8.3% · OPM 31% 95% evidence | 7.5/20 P/E 42.4× · PEG — 50% evidence | 7.6/20 RS sector -27.5% · RS bench 28% · 1Y -4.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 10 + 7.5 + 7.6 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Clean Science & Technology LtdCLEAN | 36.3/100Mixed-negative evidence94% evidence | BREAKING OUT | 4.5/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence | 18.5/25 ROCE 20.7% · OPM 36% 100% evidence | 7.8/20 P/E 38.4× · PEG 6.24 100% evidence | 5.5/20 RS sector -24.4% · RS bench 1.4% · 1Y -29.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 4.5 + 18.5 + 7.8 + 5.5 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Amines & Plasticizers LtdAMNPLST | 35.5/100Mixed-negative evidence81% evidence | ASLEEP | 7.8/35 Revenue -12.4% · PAT -3% · OPM change 0.7 pp 95% evidence | 14.0/25 ROCE 16.7% · OPM 9.9% 95% evidence | 8.8/20 P/E 23.6× · PEG — 50% evidence | 4.9/20 RS sector -19.4% · RS bench -9.2% · 1Y -27.6%5 of 10 weeks ahead 70% evidence |
| Exact sum: 7.8 + 14 + 8.8 + 4.9 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Transpek Industry LtdTRANSPEK | 34.5/100Adverse evidence81% evidence | TURNING | 6.4/35 Revenue -5.2% · PAT -29.1% · OPM change -2.3 pp 95% evidence | 9.1/25 ROCE 8.4% · OPM 13.3% 95% evidence | 11.3/20 P/E 19.3× · PEG — 50% evidence | 7.7/20 RS sector -19.7% · RS bench 11.7% · 1Y -4.7%4 of 10 weeks ahead 70% evidence |
| Exact sum: 6.4 + 9.1 + 11.3 + 7.7 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Thirumalai Chemicals LtdTIRUMALCHM | 25.9/100Adverse evidence69% evidence | BASING | 13.1/35 Revenue -5.8% · PAT -36.9% · OPM change 12 pp 71% evidence | 1.1/25 ROCE -3.1% · OPM 6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.7/20 RS sector -39.8% · RS bench -23.6% · 1Y -49%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.1 + 1.1 + 10 + 1.7 = 25.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Alkyl Amines Chemicals Ltd's share price today?
Alkyl Amines Chemicals Ltd trades at ₹1,868, −8.0% over the past year. The company is valued at ₹9,552 Cr. The stock sits at 76% of its 52-week range of ₹1,278–₹2,053, +5.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 11 September 2026.
What were Alkyl Amines Chemicals Ltd's latest quarterly results?
Alkyl Amines Chemicals Ltd reported revenue of ₹528 Cr and net profit of ₹95.0 Cr for the Jun 26 quarter. Revenue rose 30.0% and profit rose 93.9% year on year. Earnings per share were ₹18.50. The operating margin was 25.0%, 6.0 pp higher than a year earlier. — as of 11 September 2026.
What is Alkyl Amines Chemicals Ltd's revenue?
Alkyl Amines Chemicals Ltd reported revenue of ₹528 Cr in the Jun 26 quarter, +30.0% year on year. For the full FY26 fiscal year, revenue was ₹1,536 Cr (−2.3%). Over the last 10 years revenue compounded at 12.2% a year. — as of 11 September 2026.
What is Alkyl Amines Chemicals Ltd's profit?
Alkyl Amines Chemicals Ltd earned ₹95.0 Cr of net profit in the Jun 26 quarter, +93.9% year on year. Full-year FY26 profit was ₹180 Cr. The operating margin ran 25.0% in the latest quarter. — as of 11 September 2026.
What is Alkyl Amines Chemicals Ltd's market cap?
Alkyl Amines Chemicals Ltd's market capitalisation is ₹9,552 Cr at a share price of ₹1,868. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Alkyl Amines Chemicals Ltd's P/E ratio?
Alkyl Amines Chemicals Ltd trades at a P/E of 42.4×, at the 48th percentile of its own 11-year range, against a long-run median of 43.7×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Alkyl Amines Chemicals Ltd pay a dividend?
Yes — Alkyl Amines Chemicals Ltd's dividend payout was 28% of profit in FY26, and it recorded a payout in each of its last 18 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Alkyl Amines Chemicals Ltd overvalued?
On its own history, Alkyl Amines Chemicals Ltd looks mid-range: its P/E of 42.4× sits at the 48th percentile of its 11-year range (long-run median 43.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Alkyl Amines Chemicals Ltd growing?
Yes — Alkyl Amines Chemicals Ltd is growing: latest-quarter revenue +30.0% year on year, profit +93.9%, and the margin +6.0 pp at 25.0%. The 10-year compound rates are 12.2% (revenue) and 13.7% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Alkyl Amines Chemicals Ltd performing?
Alkyl Amines Chemicals Ltd is in a confirmed uptrend, 12 weeks in. Its latest quarter's revenue rose 30.0% and profit rose 93.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Alkyl Amines Chemicals Ltd in?
Improving — profit growth bottomed 8 quarters ago at −26.4% and has held its recovery at +21.0%, ROCE holding at 15.1%. The read comes from the last 12 quarters of growth (revenue growth +5.1% latest, profit growth +21.0% latest, eps growth +20.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Alkyl Amines Chemicals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading +5.0% versus its 200-day average and at 76% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Alkyl Amines Chemicals Ltd beating the market?
On recent form, yes — Alkyl Amines Chemicals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 6 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +1,349% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Alkyl Amines Chemicals Ltd's share price go up?
This page publishes no price forecast for Alkyl Amines Chemicals Ltd. What it measures instead: the share price is ₹1,868, the price is in a confirmed uptrend 12 weeks in. Its P/E of 42.4× sits at the 48th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Alkyl Amines Chemicals Ltd?
Promoters hold 72.0% of Alkyl Amines Chemicals Ltd, foreign institutions 3.5%, domestic institutions 3.1% and the public 21.4% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 2.0 points over 8 quarters. — as of 11 September 2026.
Does Alkyl Amines Chemicals Ltd have too much debt?
No — Alkyl Amines Chemicals Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹1.0 Cr against equity of ₹1,533 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Alkyl Amines Chemicals Ltd's capex?
Alkyl Amines Chemicals Ltd spent ₹276 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹121 Cr, with ₹130 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Alkyl Amines Chemicals Ltd's cash flow?
Alkyl Amines Chemicals Ltd generated ₹239 Cr of operating cash flow in FY26 and ₹118 Cr of free cash flow after ₹121 Cr of capital spending. Reported profit that year was ₹180 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Alkyl Amines Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 151% of Alkyl Amines Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹239 Cr against reported profit of ₹180 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Alkyl Amines Chemicals Ltd in its business cycle?
Alkyl Amines Chemicals Ltd's FY26 operating margin was 19.0%, against a 18-year band of 11.0%–35.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 25.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Alkyl Amines Chemicals Ltd's price assume?
At its price on 13 June 2026, Alkyl Amines Chemicals Ltd was priced for profit growth of about 24.3% a year. Profit itself has compounded 13.7% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Alkyl Amines Chemicals Ltd story?
Biggest watch item: the price is already 12 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Alkyl Amines Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Alkyl Amines Chemicals Ltd's stock has fallen further than its earnings. EPS fell 3.3% in a year while the price moved −8.0%. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!